BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18048089)

  • 41. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
    Pawlak K; Mysliwiec M; Pawlak D
    Thromb Res; 2010 Feb; 125(2):e40-5. PubMed ID: 19732942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
    Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
    Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells.
    Bruse C; Guan Y; Carlberg M; Carlström K; Bergqvist A
    Fertil Steril; 2005 Apr; 83 Suppl 1():1155-60. PubMed ID: 15831288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
    Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
    J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study.
    Nahon P; Sutton A; Rufat P; Faisant C; Simon C; Barget N; Trinchet JC; Beaugrand M; Gattegno L; Charnaux N
    Eur J Gastroenterol Hepatol; 2007 May; 19(5):425-31. PubMed ID: 17413295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous evaluation of circulating chemokine and cytokine profiles in elderly subjects by multiplex technology: relationship with zinc status.
    Mariani E; Cattini L; Neri S; Malavolta M; Mocchegiani E; Ravaglia G; Facchini A
    Biogerontology; 2006; 7(5-6):449-59. PubMed ID: 16967203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
    Gårdsvoll H; Werner F; Søndergaard L; Danø K; Ploug M
    Protein Expr Purif; 2004 Apr; 34(2):284-95. PubMed ID: 15003263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasminogen activation by fibroblasts from periodontal ligament and gingiva is not directly affected by chemokines in vitro.
    Sarajlic J; Agis H; Kandler B; Watzek G; Gruber R
    Arch Oral Biol; 2007 Jul; 52(7):663-8. PubMed ID: 17296163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment.
    Bandinelli F; Del Rosso A; Gabrielli A; Giacomelli R; Bartoli F; Guiducci S; Matucci Cerinic M
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S44-9. PubMed ID: 22691208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome.
    Kasperska-Zajac A; Rogala B
    Inflammation; 2005 Apr; 29(2-3):90-3. PubMed ID: 16858643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5.
    Leach K; Charlton SJ; Strange PG
    Biochem Pharmacol; 2007 Sep; 74(6):881-90. PubMed ID: 17645873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
    Eugen-Olsen J; Gustafson P; Sidenius N; Fischer TK; Parner J; Aaby P; Gomes VF; Lisse I
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):686-92. PubMed ID: 12150480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells.
    Pharoah DS; Varsani H; Tatham RW; Newton KR; de Jager W; Prakken BJ; Klein N; Wedderburn LR
    Arthritis Res Ther; 2006; 8(2):R50. PubMed ID: 16507178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
    Thromb Res; 2005; 115(4):277-85. PubMed ID: 15668187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inflammation but not oxidative stress is associated with beta-chemokine levels and prevalence of cardiovascular disease in uraemic patients.
    Pawlak K; Pawlak D; Myśliwiec M
    Cytokine; 2006 Sep; 35(5-6):258-62. PubMed ID: 17070067
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in the seminal plasma and sperm of fertile and oligoasthenozoospermia males].
    Wang L; Guan HT; Tian YH; Xiong CL
    Zhonghua Nan Ke Xue; 2006 Sep; 12(9):791-3. PubMed ID: 17009528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.